HomeAI · summaries
Storia in 2 fonti
Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study
Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, even in patients who previously received Novartis' Pluvicto. Response rates were higher in patients without prior Pluvicto treatment. Larger trials are planned to assess side effects. Novartis is increasing its focus on radioligand therapies.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
economictimes.indiatimes.com
Novartis experimental actinium-based drug shows promise in prostate cancer treatment: Study
Novartis' new experimental actinium-based drug shows promise against prostate cancer. Early data on Sunday revealed anti-tumour activity, even in patients who previously received…
- ·
semana.com
Novartis avanza en tratamiento contra el cáncer de próstata con resultados positivos de Pluvicto
El medicamento Pluvicto logró retrasar la progresión de la enfermedad en pacientes con cáncer de próstata metastásico sensible a hormonas, según un ensayo de fase avanzada.